News

The transaction will enhance Hi-Tech’s leading Sports Nutrition arsenal and expand its distribution through iForce’s strong distribution network. Hi-Tech chairman, president and CEO Jared Wheat said: "The combination

CINRYZE received the designation for investigation in the treatment of antibody mediated rejection (AMR) in patients receiving kidney transplants. The injectable prescription medicine is used to help prevent

Drug Modification Technology (DMT) platform can help address sub-optimal physico-chemical and pharmacokinetic properties of approved drugs and drugs in development. Sphaera’s technology allows for improved delivery of a

The approved medicines include trastuzumab (Herceptin) for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis (a long term

The firm has enrolled the patients using suprachoroidal space (SPS) drug administration in the trial, which is designed to assess CLS-TA to treat macular edema associated with non-infectious

Gamida will use the money to advance its clinical programs, including the development of NiCord, an experimental treatment for patients with high risk hematological malignancies or blood cancers

The company said that the drug was being explored for the treatment of high-risk atherosclerotic cardiovascular disease. Lilly Bio-Medicines senior vice president and president David Ricks said: "We’re

The regulator has granted the filing accelerated assessment, under which it intends to provide a scientific opinion on the submission in a reduced time frame of 150 days.

Under the expanded deal, the firms will work together to develop and commercialize up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next ten years,